BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma Inc.

BridgeBio Pharma received a Hold rating and price target from Citi analyst today. In addition to Citi, BridgeBio Pharma also received a Hold from J...

BridgeBio Pharma (BBIO) Gets a Hold from Citi

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BB...

Analysts Offer Insights on Healthcare Companies: Cardiol Therapeutics (CRDL) and BridgeBio Pharma (BBIO)

The latest announcement is out from BridgeBio Pharma ( ($BBIO) ). On May 7, 2026, BridgeBio Pharma, Inc. filed an automatic shelf registration stat...

BridgeBio Pharma Launches New $500 Million ATM Program

BridgeBio Pharma ( ($BBIO) ) just unveiled an announcement. BridgeBio reported first-quarter 2026 revenue of $194.5 million, largely driven by $180...

BridgeBio Pharma Announces $500 Million Stock Repurchase Program

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN) and BridgeBio Pharma (BBIO) with bullis...

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), BridgeBio Pharma (BBIO)

Barclays analyst Eliana Merle maintained a Buy rating on BridgeBio Pharma today and set a price target of $157.00. According to TipRanks, Merle is ...

BridgeBio Pharma (BBIO) Gets a Buy from Barclays

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Qiagen (QGEN) and BridgeBio Pharma (BBIO). Qiagen (QGEN) In a rep...

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN) and BridgeBio Pharma (BBIO)

With markets stabilizing and investors moving back to high-growth names, a handful of companies are standing out for their strong momentum, improvi...

Market Cap	$12.92B	P/E Ratio	N/A
52W High	$84.94	52W Low	$31.77
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	9.6%	52W Position	66.3%
Overall Score	44	Value Score	40
Quality Score	52	Technical Score	40

EPS Current Est	$-2.27	EPS Next Est	$0.25
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BBIO	$67.04	-3.01%	1.25M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BBIO	$67.04	-3.0%	1.25M
3
4
5
6

BBIO

BBIO

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get BridgeBio Pharma Inc. Data in Excel

Get BridgeBio Pharma Inc. Data in Excel